Editas Medicine, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Editas Medicine, Inc. on December 10, 2018, covering events that occurred on December 6 and December 7, 2018. The filing pertains to changes in the composition of the Company's Board of Directors.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on corporate governance changes.
Material Changes
- Appointment of Director: On December 6, 2018, the Board appointed Cynthia Collins as a Class II director. Her term will last until the 2021 Annual Meeting of Stockholders or until her successor is elected.
- Resignation of Director: On December 7, 2018, Boris Nikolic, M.D., resigned from the Board.
Compensation and Background
Cynthia Collins Background: Ms. Collins previously served as CEO of Human Longevity, Inc. (2017), CEO of GE Healthcare Life Sciences' Cell Therapy division (2015-2016), and CEO of GenVec, Inc. (2012-2013). She currently serves on the boards of Cavidi AB, Triumvira Immunologics, Inc., DermTech, Inc., and Biocare Medical, LLC.
Compensation Arrangement:
- Annual cash compensation: $35,000.
- Stock option: 23,076 shares of common stock at the closing price on the date of appointment.
- Vesting: One-third of shares vest annually over three years, contingent on continued service.
- Expenses: Reimbursement for reasonable travel and meeting-related costs.
Outlook, Risks, and Contingencies
The filing does not contain management commentary on business outlook, specific risks, or contingencies beyond the standard indemnification agreement entered into by the new director.
Key Facts for Investor Verification
- Verify the impact of the Board composition change on the Company's strategic direction.
- Confirm the vesting schedule and exercise price of the stock options granted to Cynthia Collins.
- Review the Company's proxy statements for details on the resignation of Boris Nikolic, M.D.